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Abstract: Although human exposure to Gram-negative Vibrio vulnificus (V. vulnificus) 
lipopolysaccharide (LPS) has been reported to result in septic shock, its impact on the 
central nervous system’s innate immunity remains undetermined. The purpose of this study 
was to determine whether V. vulnificus MO6-24/O LPS might activate rat microglia  
in vitro and stimulate the release of superoxide anion (O2
−
), a reactive oxygen species 
known to cause oxidative stress and neuronal injury in vivo. Brain microglia were isolated 
from neonatal rats, and then treated with either V. vulnificus MO6-24/O LPS or 
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Escherichia coli O26:B6 LPS for 17 hours in vitro. O2
−
 was determined by cytochrome C 
reduction, and matrix metalloproteinase-2 (MMP-2) and MMP-9 by gelatinase 
zymography. Generation of cytokines tumor necrosis factor alpha (TNF-α),  
interleukin-1 alpha (IL-1α), IL-6, and transforming growth factor-beta 1 (TGF-β1), 
chemokines macrophage inflammatory protein (MIP-1α)/chemokine (C-C motif) ligand 3 
(CCL3), MIP-2/chemokine (C-X-C motif) ligand 2 (CXCL2), monocyte chemotactic 
protein-1 (MCP-1)/CCL2, and cytokine-induced neutrophil chemoattractant-2alpha/beta 
(CINC-2α/β)/CXCL3, and brain-derived neurotrophic factor (BDNF), were determined by 
specific immunoassays. Priming of rat microglia by V. vulnificus MO6-24/O LPS in vitro 
yielded a bell-shaped dose-response curve for PMA (phorbol 12-myristate  
13-acetate)-stimulated O2
−
 generation: (1) 0.1–1 ng/mL V. vulnificus LPS enhanced O2
−
 
generation significantly but with limited inflammatory mediator generation;  
(2) 10–100 ng/mL V. vulnificus LPS maximized O2
−
 generation with concomitant release 
of thromboxane B2 (TXB2), matrix metalloproteinase-9 (MMP-9), and several cytokines 
and chemokines; (3) 1000–100,000 ng/mL V. vulnificus LPS, with the exception of TXB2, 
yielded both attenuated O2
−
 production, and a progressive decrease in MMP-9, cytokines 
and chemokines investigated. Thus concentration-dependent treatment of neonatal brain 
microglia with V. vulnificus MO6-24/O LPS resulted in a significant rise in O2
−
 production, 
followed by a progressive decrease in O2
−
 release, with concomitant release of lactic 
dehydrogenase (LDH), and generation of TXB2, MMP-9, cytokines and chemokines. We 
hypothesize that the inflammatory mediators investigated may be cytotoxic to microglia  
in vitro, by an as yet undetermined autocrine mechanism. Although V. vulnificus LPS was 
less potent than E. coli LPS in vitro, inflammatory mediator release by the former was 
clearly more efficacious. Finally, we hypothesize that should V. vulnificus LPS gain entry 
into the CNS, it would be possible that microglia might become activated, resulting in high 
levels of O2
−
 as well as neuroinflammatory TXB2, MMP-9, cytokines and chemokines. 
Keywords: LPS; Escherichia coli; Vibrio vulnificus; rat microglia; cytokine; chemokine; 
superoxide; thromboxane; metalloproteinase; neuroinflammation; MMP-9 
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transforming growth factor β1; TNF-α, tumor necrosis factor; TXB2, thromboxane B2; V. vulnificus, 
Vibrio vulnificus. 
1. Introduction 
Vibrio vulnificus (V. vulnificus) is a virulent halophilic motile Gram-negative bacterium present in 
marine, estuarine and aquaculture warm water environments worldwide [1,2]. V. vulnificus may infect 
humans through contaminated seafood or skin wounds, causing gastroenteritis, necrotic skin 
infections, primary septicemia, with fatality rates reported to exceed 50% [2,3], and meningitis [4,5]. 
Although combination antimicrobial therapy of V. vulnificus meningitis has resulted in effective 
treatment [5], antibiotic resistance in V. vulnificus is a definite concern [3,6]. Clinical and 
environmental sources of V. vulnificus, which include pathogenic as well as non-pathogenic strains, are 
currently divided into three biotypes [7,8]. Interestingly, because the biotype of V. vulnificus isolated 
from cerebrospinal fluid in meningoencephalitis and meningitis cases was not characterized, a 
correlation between clinical and environmental V. vulnificus biotypes and potential brain infections in 
humans remains presently undetermined [4,5].  
Research into the chemistry and immunotoxicology of V. vulnificus lipopolysaccharides (LPS) was 
initiated more than two decades ago with the isolation of V. vulnificus LPS [9]. Previous studies have 
investigated both the O-polysaccharide or O-antigen of the LPS molecule, which are responsible for 
immunogenicity [10], as well as the lipid A moiety which is associated with Gram-negative septic 
shock [11]. Several studies on the pathogenicity of V. vulnificus LPS in mice and rats have revealed 
that it may be pyrogenic and cause cardiovascular injury [10,12,13], which may progress to septic 
shock and high mortality [10,14], pathological conditions which have been shown to be affected by 
chronic iron overload, estrogen and low-density lipoprotein [15–18]. V. vulnificus Biotype 1, strain 
MO6-24/O, which has been shown to be lethal to mice [14] and to induce both interleukin-6 mRNA 
and tumor necrosis factor-α (TNF-α) release from human peripheral blood mononuclear cells [19], was 
used in this study. To our knowledge, there is no report in the literature that has determined the effect 
of V. vulnificus LPS on brain microglia, the main cell type involved in neuroinflammation [20]. 
In humans, Gram-negative infections and release of LPS in the circulation may result in a systemic 
inflammatory response that contributes to sepsis and refractory septic shock [21] and may also impact 
the brain [22]. Furthermore, if LPS causes a pathological disruption of the blood-brain barrier  
(BBB) [23] or penetrates the brain via regions where the BBB is defective, it may activate brain 
microglia [24]. When microglia are activated by LPS via interaction with the CD14 receptor and  
Toll-like receptor 4 [22,25], inflammatory mediators are released including reactive oxygen species,  
e.g., O2
−
 [26,27], which may cause neuronal injury [28], and progressive neurodegeneration [29,30]. To 
our knowledge no studies have been completed to determine the effect of V. vulnificus LPS on brain 
microglia O2
−
 generation. 
The purpose of this investigation was to test the hypothesis that in vitro treatment of neonatal rat 
microglia with V. vulnificus MO6-24/O LPS might stimulate release of O2
−
, a reactive oxygen species 
hypothesized to be associated with brain injury [31]. Together with our preliminary  
communications [32–34], the current study provides experimental support for our working hypothesis, 
namely that V. vulnificus LPS primes rat brain microglia in vitro for O2
−
 generation. Furthermore, O2
−
 
Mar. Drugs 2014, 12 1735 
 
 
generation appeared to be concomitant with the release of several pro-inflammatory mediators, namely 
thromboxane B2 and matrix metalloproteinases, as well as several cytokines and chemokines.  
2. Results 
2.1. Effect of V. vulnificus LPS on Rat Brain Microglia O2
−
 Generation 
Microglia reactive oxygen species generation has been reported to be associated with oxidative 
stress in chronic neurodegenerative diseases [35–37]. We have repeatedly observed that E. coli LPS 
pre-treatment primes rat microglia for agonist-stimulated O2
−
 generation in vitro [27,38]. As shown in 
Figure 1, untreated microglia release low levels of O2
−
 after phorbol 12-myristate 13-acetate (PMA) 
stimulation. However, when E. coli LPS-treated microglia were stimulated with PMA, O2
−
 generation 
was bell-shaped with maximal O2
−
 at 1 ng/mL LPS (9.98 ± 1.6 nmoles O2
−
, n = 14, P < 0.001), 
confirming our previous observations [27]. In contrast, when microglia were pre-treated with  
V. vulnificus LPS for 17 h, concentration-dependent O2
−
 release became maximal at 10 ng/mL  
V. vulnificus LPS (8.6 ± 1.4 nmoles O2
−
, n = 13, P < 0.001), and then progressively decreased. Thus  
V. vulnificus LPS appeared to be approximately a tenth less potent than E. coli LPS in stimulating O2
−
 
production from microglia in vitro.  
Figure 1. The effect of E. coli and V. vulnificus lipopolysaccharide (LPS) on rat microglia 
phorbol 12-myristate 13-acetate (PMA)-stimulated O2
−
 release. Neonatal rat microglia  
(2 × 10
5
 cells/well) were treated with E. coli LPS (0.1–100 ng/mL) or V. vulnificus LPS 
(0.1–105 ng/mL) for 17 h in vitro, and then stimulated with PMA (1 μM) for 70 min. O2
−
 
was determined as described in Experimental Section. Data expressed as nanomoles O2
−
 is 
the mean ± SEM of 13–14 independent experiments (n), each experiment with duplicate 
determinations. ** P < 0.01, *** P < 0.001 versus untreated control (0). 
▲
 P < 0.05,  
▲▲
 P < 0.01 V. vulnificus LPS vs. E. coli LPS. 
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2.2. Effect of V. vulnificus LPS on Rat Brain Microglia LDH Generation 
In order to determine whether the progressive decrease in O2
−
 release shown in Figure 1 was caused 
by toxicity of E. coli or V. vulnificus LPS to microglia, we measured the presence of lactate 
dehydrogenase (LDH), a marker for cellular toxicity, in microglia tissue culture supernatants after the 
17 h in vitro incubation [39].  
As shown in Figure 2, there was a dose-dependent increase in LDH release in vitro that paralleled 
the decrease in O2
−
 generation observed with increasing E. coli or V. vulnificus LPS concentrations. 
Thus in E. coli LPS-pretreated microglia, statistically significant LDH release was observed at  
100 ng/mL LPS (73.6 ± 8.4% of control, n = 12, P < 0.001). In contrast, in V. vulnificus  
LPS-pretreated microglia, a maximum of 70.3 ± 16% of control LDH release was observed at  
10
4
 ng/mL (n = 12, P < 0.01).  
Figure 2. The effect of E. coli and V. vulnificus LPS on rat microglia lactate 
dehydrogenase (LDH) release. Neonatal rat microglia (2 × 105 cells/well) were treated with 
either E. coli LPS (0.1–100 ng/mL) or V. vulnificus LPS (0.1–105 ng/mL) for 17 h  
in vitro. LDH release was determined as described in Experimental Section. Data 
expressed as % of Triton X-100 0.1% treated microglia LDH release is the mean ± SEM of 
12–13 independent experiments (n), each experiment with duplicate determinations.  
** P < 0.01, *** P < 0.001 versus untreated control (0). 
 
2.3. Effect of V. vulnificus LPS on Rat Brain Microglia TXB2 Generation 
Release of eicosanoids by activated microglia appears to play a significant role in 
neuroinflammation [26], and E. coli LPS-treated rat microglia generate TXB2 in vitro [27,40]. As 
depicted in Figure 3, unstimulated microglia released low levels of TXB2 (550 ± 200 pg/mL, n = 8). 
Confirming prior observations [27,38], when microglia were pre-treated with 100 ng/mL E. coli LPS, 
high concentrations of TXB2 were detected in the tissue culture supernates (5504.5 ± 1881 pg/mL 
TXB2, n = 7, P < 0.01), which was concomitant with attenuated O2
−
 generation (Figure 1), and 
enhanced LDH release (Figure 2). In contrast, V. vulnificus LPS-treated microglia TXB2 generation 
yielded a sigmoid curve, and became statistically significant at 10
5
 ng/mL LPS (4731 ± 1475 pg/mL 
TXB2 n = 7, P < 0.05), when there was minimal O2
−
 generation (Figure 1) and high LDH release 
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(Figure 2). Thus, although V. vulnificus LPS appeared less potent than E. coli LPS in inducing a 
concentration-dependent TXB2 release from rat microglia in vitro, it was as effective as E. coli LPS, 
because maximal TXB2 release was of a similar magnitude.  
Figure 3. The effect of E. coli and V. vulnificus LPS on rat microglia thromboxane B2 
(TXB2) release. Neonatal rat microglia (2 × 10
5
 cells/well) were treated with E. coli LPS 
(0.1–100 ng/mL) or V. vulnificus LPS (0.1–105 ng/mL) for 17 h in vitro. TXB2 was 
determined as described in Experimental Section. Data expressed as TXB2 pg/mL is the 
mean ± SEM of seven independent experiments (n), each experiment with duplicate 
determinations. * P < 0.05, ** P < 0.01 versus untreated control (0). 
 
2.4. Effect of V. vulnificus LPS on Rat Brain Microglia MMP-2 and MMP-9 Generation 
Matrix metalloproteinases (MMP) released by activated microglia have been proposed to be 
proinflammatory in both sepsis and neuroinflammation [41,42]. We, and others, have observed  
MMP-2 and MMP-9 generation by E. coli LPS-stimulated rat microglia in vitro [27,43]. As shown in  
Figure 4, in E. coli LPS-stimulated microglia, MMP-9 levels were statistically significant at the 
following LPS concentrations (ng/mL): One (2.0 ± 0.12-fold, n = 5, P < 0.001), and  
10 (1.64 ± 0.15-fold, n = 5, P < 0.01), respectively. Similarly, microglia stimulated with V. vulnificus 
LPS for 17 h demonstrated a concentration-dependent increase of MMP-9, but not of MMP-2, at the 
following LPS concentrations (ng/mL): 10 (3.1 ± 0.5- fold, n = 5, P < 0.05), and 100 (4.0 ± 0.9-fold,  
n = 5, P < 0.01). Thus while V. vulnificus LPS was a tenth less potent than E. coli LPS in inducing a  
concentration-dependent release of MMP-9, it was more effective than E. coli LPS, because maximal 
release MMP-9 was two-fold higher.  
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Figure 4. The effect of E. coli and V. vulnificus LPS on rat microglia matrix 
metalloproteinase-2 (MMP-2) and -9 release. Neonatal rat microglia (2 × 10
5
 cells/well) 
were treated with E. coli LPS (0.1–100 ng/mL) or V. vulnificus LPS (0.1–105 ng/mL) for 
17 h in vitro. As described in Experimental Section, MMP-2 and MMP-9 were determined 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) zymography 
(panel A), and quantitated results for E. coli LPS (panel B) and for V. vulnificus LPS  
(panel C) are depicted in the bar graphs. Data is expressed as mean ± SEM of normalized 
MMP release from five independent experiments (n). * P < 0.05, ** P < 0.01,  
*** P < 0.001 versus untreated control (0). 
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2.5. Effect of V. vulnificus LPS On Rat Brain Microglia Cytokines IL-6, TNF-α and IL-1α Release 
After a 17 h in vitro incubation, both E. coli and V. vulnificus LPS-treated microglia released the 
inflammatory cytokines IL-6, TNF-α, and IL-1α into the tissue culture supernates, in the following 
decreasing concentrations (pg/mL): IL-6 > TNF-α > IL-1α. 
The cytokine IL-6 has been shown to play a role in the immune response, inflammation and 
hematopoiesis [44], and in neuroimmunomodulation in Alzheimer’s disease [45]. E. coli LPS has been 
reported to stimulate human [46], murine [47] and rat [43,48] microglia to release IL-6 in vitro. In our 
investigation, unstimulated microglia released low levels of IL-6 (71.7 ± 35 pg/mL, n = 4). As shown 
in Figure 5 (Panel A), IL-6 levels in E. coli LPS-stimulated microglia were significant at 1 ng/mL LPS 
(9733 ± 2539 pg/mL IL-6, n = 4, P < 0.05). In V. vulnificus LPS-stimulated microglia, IL-6 levels 
became statistically significant at 100 ng/mL (21,605 ± 5864 pg/mL IL-6, n = 4, P < 0.001). Thus,  
V. vulnificus LPS appeared to be a hundredth less potent than E. coli LPS in inducing  
concentration-dependent release of IL-6 from rat microglia in vitro, but was more efficacious than  
E. coli LPS, because maximal release of IL-6 was 78% higher.  
The cytokine TNF-α has been shown to play an important role in normal brain function as well as in 
neurodegenerative disease [49]. Treatment of human [46], murine [47,50], and rat microglia [27,48] 
with E. coli LPS in vitro resulted in TNF-α release. In our present investigation, unstimulated rat 
microglia released low levels of TNF-α (16.5 ± 7.9 pg/mL, n =6). As shown in Figure 5 (Panel B), in 
E. coli LPS-stimulated microglia, a concentration-dependent TNF-α release became statistically 
significant at 1 ng/mL LPS (4363 ± 961 pg/mL TNF-α, n = 5, P < 0.001), thus confirming our previous 
observations [27]. In contrast, in V. vulnificus LPS-stimulated rat microglia cells, TNF-α release was 
significant at 100 ng/mL, and peaked at 1000 ng/mL (8547 ± 3570 pg/mL TNF-α, n = 6, P < 0.01). 
Thus, similar to O2
−
 (Figure 1) and TXB2 (Figure 3), V. vulnificus LPS appeared to be a hundredth less 
potent than E. coli LPS in inducing TNF-α production from rat microglia in vitro, and yet  
V. vulnificus LPS was clearly more efficacious than E. coli LPS, because maximal TNF-α release was 
132% higher.  
The cytokine IL-1α has been proposed as a key mediator in inflammatory neurodegeneration and 
neuronal injury [51,52]. E. coli LPS primes rat microglia to release IL-1α in vitro [53]. In our present 
study, unstimulated microglia released low levels of IL-1α (9.2 ± 5.1 pg/mL, n = 4). As shown in 
Figure 5 (Panel C), in E. coli LPS-stimulated microglia, IL-1α levels peak at 10 ng/mL  
(825.7 ± 234.6 pg/mL IL-1α, n = 4, P < 0.01). In contrast, in V. vulnificus LPS-stimulated microglia, 
IL-1α levels become statistically significant at 100 ng/mL (1669.7 ± 473.3 pg/mL IL-1α, n = 4,  
P < 0.01). Thus, although V. vulnificus LPS was a tenth less potent than E. coli LPS in inducing IL-1α 
generation from rat microglia in vitro, as observed for TNF-α (Figure 5, panel B) generation, the 
overall magnitude of the V. vulnificus LPS response was higher than E. coli LPS, with an increase in 
maximal release of IL-1α of 102%.  
  
Mar. Drugs 2014, 12 1740 
 
 
Figure 5. The effect of E. coli and V. vulnificus LPS on rat microglia cytokines IL-6, 
tumor necrosis factor-alpha (TNF-α) and interleukin-one alpha (IL-1α) release. Neonatal 
rat microglia (2 × 10
5
 cells/well) were treated with E. coli LPS (0.1–100 ng/mL) or  
V. vulnificus LPS (0.1–105 ng/mL) for 17 h in vitro. IL-6 (Panel A), TNF-α (Panel B), and 
IL-1α (Panel C) were determined as described under Experimental Section. Data expressed 
as pg/mL is the mean ± SEM of values from four to six independent experiments (n), each 
experiment with duplicate determinations. * P < 0.05, ** P < 0.01, *** P < 0.001 versus 
untreated control (0). 
▲
 P < 0.05, ▲▲ P < 0.01, ▲▲▲ P < 0.001, ▲▲▲▲ P < 0.0001  
V. vulnificus LPS vs. E. coli LPS. 
 
  
 
 
 
 
 
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0
3 0 0 0 0 E . C o li L P S
V . V u ln if ic u s  L P S
0 0 .1 1 10 10
2
10
3
10
4
10
5 [n g /m l]
IL
-6
 [
p
g
/m
l]
*
***
**
**
 
T
N
F

 [
p
g
/m
l]
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0
1 2 0 0 0
1 4 0 0 0
E . c o li L P S
V . V u ln if ic u s  L P S
10
2
10
3
10
4
10
5
0 0 .1 1 10 [n g /m l]
*
***
**
***
***
 
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
E .c o li L P S
V .V u ln if ic u s  L P S
0 0 .1 1 10
2
10
3
10
4
10 10
5
IL
-1

 [
p
g
/m
l]
**
**
**
** **
[n g /m l]
A 
B 
C 
Mar. Drugs 2014, 12 1741 
 
 
2.6. Effect of V. vulnificus LPS on Rat Brain Microglia MIP-2/CXCL2, MIP-1α/CCL3, CINC-2α/β 
(CXCL3) and MCP-1/CCL2 Generation 
E. coli and V. vulnificus LPS-treated microglia released several inflammatory chemokines into the 
tissue culture supernates after a 17 h in vitro incubation in the following decreasing concentrations 
(pg/mL): MIP-2/CXCL2 > MIP-1α/CCL3 > CINC-2α/β (CXCL3) > MCP-1/CCL2. 
The chemokine MIP-2 or CXCL2, which is involved in neuroinflammation [54], has been reported 
to be released by LPS-treated murine [47,55] and rat [56] microglia in vitro. Unstimulated microglia 
released low levels of MIP-2 constitutively (560 ± 302 pg/mL, n = 3). As shown in Figure 6 (Panel A), 
MIP-2/CXCL2 levels in E. coli LPS-stimulated microglia rose after 0.1 ng/mL LPS, and were 
maximal at 10 ng/mL LPS (77,951 ± 13,927 pg/mL MIP-2/CXCL2, n = 3, P < 0.01). In V. vulnificus 
LPS-stimulated microglia, MIP-2/CXCL2 release progressively increased at 10 ng/mL LPS, and 
became statistically significant at 100 ng/mL (131,581 ± 54,023 pg/mL MIP-2/CXCL2, n = 3,  
P < 0.05). Thus, similar to the cytokines TNF-α, IL-1α and IL-6, V. vulnificus LPS was less potent 
than E. coli LPS in inducing concentration-dependent release of the chemokine MIP-2/CXCL2 in vitro 
but more efficacious because maximal release was 73% higher. 
The chemokine MIP-1α or CCL3, involved in CNS inflammation [54] and in multiple  
sclerosis [57], has been reported to be generated by LPS-treated mouse [47,50], rat [58] and human 
microglia cells in vitro [59]. As shown in Figure 6 (Panel B), E. coli LPS-induced MIP-1α/CCL3 
release occurred at greater than 0.1 ng/mL and was significant at 1 ng/mL (47,464.9 ± 4298.8 pg/mL 
MIP-1α/CCL3, n = 3, P < 0.001). V. vulnificus LPS-stimulated MIP-1α/CCL3 release, which was 
statistically significant at 10 ng/mL (18,936 ± 6142 pg/mL MIP-1α/CCL3, n = 4, P < 0.05), peaked at 
100 ng/mL. Thus V. vulnificus LPS was a tenth less potent than E. coli LPS in inducing MIP-1α/CCL3 
release from rat microglia. Interestingly, and in contrast to TNF-α, IL-1-α, IL-6 and MIP-2 release by 
microglia stimulated by E. coli LPS, the effect of V. vulnificus LPS on the release of MIP-1α/ CCL3 
was diminished by 45%.  
The chemokine cytokine-induced neutrophil chemoattractant (CINC)-2α/β or CXCL3, earlier 
known as growth-regulated oncogene or GRO, plays a role in chemotaxis and inflammation in the 
CNS [60]. Although human microglia released GRO α in vitro [61], the effect of LPS on microglia and 
CINC-2α/β (CXCL3) generation has not been investigated to our knowledge. As shown in Figure 6 
(Panel C), E. coli LPS-induced CINC-2α/β (CXCL3) release peaked at 10 ng/mL (16,864 ± 5792 
pg/mL CINC-2α/β (CXCL3), n = 2, P < 0.05). V. vulnificus LPS-induced CINC-2α/β (CXCL3) release 
was statistically significant at 100 ng/mL (27,910 ± 10,443 pg/mL CINC-2α/β (CXCL3), n = 2,  
P < 0.01). Thus, similar to TNF-α, IL-1α, IL-6, and MIP-2, V. vulnificus LPS was a tenth less potent 
than E. coli LPS in inducing concentration-dependent release of the chemokine CINC-2α/β (CXCL3) 
in vitro, but more effective because maximal release was 65% higher. 
The chemokine MCP-1 or CCL2, which plays a role in both neuroinflammation [54] and multiple 
sclerosis [57], is released by murine [47], rat [48,58] and human microglia in vitro [59]. Unstimulated 
microglia released low levels of MCP-1/CCL2 constitutively (17 ± 9 pg/mL, n = 3). As shown in 
Figure 6 (Panel D), E. coli LPS-induced MCP-1/CCL2 release yielding a bell-shaped curve which 
peaked at 1 ng/mL (441 ± 149 pg/mL MCP-1/CCL2, n = 3, P < 0.05). Similarly, V. vulnificus  
LPS-induced MCP-1/CCL2 release was statistically significant at 100 ng/mL (506 ± 193 pg/mL  
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MCP-1/CCL2, n = 4, P < 0.05). Although V. vulnificus LPS was a hundredth less potent than E. coli 
LPS at inducing concentration-dependent release of the chemokine MCP-1/CCL2, maximal observed 
release was similar.  
Figure 6. The effect of E. coli and V. vulnificus LPS on rat microglia chemokines 
macrophage inflammatory protein-2 (MIP-2)/chemokine (C-X-C motif) ligand 2 (CXCL2), 
MIP-1α/chemokine (C-C motif) ligand 3 (CCL3), CINC-2α/β/CXCL3 and monocyte 
chemotactic protein-1 (MCP-1)/CCL2 release. Neonatal rat microglia (2 × 10
5
 cells/well) 
were treated with E. coli (0.1–100 ng/mL) or V. vulnificus (0.1–105 ng/mL) LPS for 17 h  
in vitro. MIP-2/CXCL2 (Panel A), MIP-1α/CCL3 (Panel B), CINC-2α/β/CXCL3 (Panel C) 
and MCP-1/CCL2 (Panel D) release was determined as described in Experimental Section. 
Data expressed as pg/mL is the mean ± SEM of two to four independent experiments (n), 
each experiment with duplicate determinations. * P < 0.05; ** P < 0.01; *** P < 0.001 
versus untreated control (0). 
▲
 P < 0.05, ▲▲▲▲ P < 0.0001 V. vulnificus LPS vs.  
E. coli LPS. 
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Figure 6. Cont. 
 
2.7. Effect of V. vulnificus LPS on Rat Brain Microglia TGF-β1 and BDNF 
In order to determine whether V. vulnificus LPS affected release of anti-inflammatory cytokines and 
neurotrophins into the conditioned medium [35], we investigated the presence of TGF-β1 and BDNF 
which have been studied for their neuroprotective effects [62], and have been shown to be expressed 
constitutively in rat microglia [63], and in vitro in E. coli LPS-activated human [64] and murine [65] 
microglia. As shown in Table 1, unstimulated rat microglia released TGF-β1 constitutively  
(320 ± 50 pg/mL, n = 3), but in contrast there was no detectable BDNF. Furthermore, V. vulnificus 
LPS but not E. coli LPS significantly enhanced TGF-β1 release from microglia after the 17 h in vitro 
incubation (973.5 ± 264.5 pg/mL TGF-β1, (n = 2), p < 0.001). No significant increase of BDNF was 
observed in either E. coli or V. vulnificus LPS-treated microglia (n = 2).  
Table 1. The effect of E. coli and V. vulnificus LPS on rat microglia TGF-β1 and  
brain-derived neurotrophic factor (BDNF) release. 
 TGF-β1 Release  BDNF Release  
LPS E. coli   V. vulnificus  E. coli   V. vulnificus  
(ng/mL) (pg/mL) n 1 (pg/mL) n 1 (pg/mL) n 1 (pg/mL) n 1 
0 319.7 ± 50.1 3 319.7 ± 50.1 3 0 2 0 2 
0.1 424.3 ± 40.3 3 386 ± 16.0 2 5.1 ± 4.4 2 1.4 ± 0.8 2 
1 363.3 ± 36 3 419 ± 66.9 3 18.4 ± 14.9 2 10.2 ± 6.2 2 
10 318.7 ± 73.2 3 358 ± 50.1 3 6.9 ± 3.9 2 6.5 ± 5.5 2 
100 333.3 ± 58.6 3 310 ± 51.6 3 6.6 ± 3.0 2 9.1 ± 4.7 2 
1000 ND  352 ± 55.5 3 ND  7.5 ± 7.5 2 
10,000 ND  613 ± 58.7 3 ND  0 ± 0 2 
100,000 ND  973.5 ± 264.5 *
 
2 ND  2.05 ± 2.05 2 
1 Rat microglia (2 × 105 cells/well) were treated with E. coli LPS (0.1–100 ng/mL) or V. vulnificus LPS  
(0.1–105 ng/mL) for 17 h in vitro. TGF-β1 and BDNF were determined as described in Experimental Section. 
Data expressed as pg/mL and is the mean ± SEM of 3 and 2 independent experiments (n) for TGF-β1 and 
BDNF, respectively, each experiment with duplicate determinations. * P < 0.001 versus untreated control (0). 
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2.8. V. vulnificus LPS Isolation and Chemical Analyses 
In order to determine whether the results reported in Figures 1–6 and Table 1 might reflect a 
chemical difference between E. coli vs. V. vulnificus LPS, Vibrio vulnificus strain MO6-24/O cells 
were extracted according two different methodologies; the extracts were checked by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) electrophoresis (Figure 7) and the gels were 
stained with the silver nitrate protocol. Alcian blue was used as fixative in one case to detect the 
occurrence of acidic polysaccharide [66]. As expected, lipooligosaccharide (LOS, 162 mg, Figure 7 
Lanes B and F) was recovered after PCP (Petroleum ether–Chloroform–aqueous phenol) extraction of 
cells. The remaining pellet was extracted according to the hot water/phenol protocol. The silver stained  
SDS-PAGE profile of the crude extract of the water layer (Figure 7, Lane H) contained a dense 
banding spread throughout the gel, while comparison of the same sample stained applying Alcian blue 
fixative first suggested the occurrence of a polysaccharide (PS) in the upper part of the gel (Figure 7, 
Lane D). To confirm this hypothesis, the crude sample (219 mg) was treated with DNAse, RNAse and 
proteinase K; SDS-PAGE control of the purified sample (79 mg) indeed showed that the dense 
banding was lost (Figure 7, Lane G) while the use of the fixative gave a positive and intense staining 
of the PS (Figure 7, Lane C). In addition, SDS-PAGE profiles showed that LOS was pure and not 
contaminated from the acidic polysaccharide, while minimal traces of LOS were seen in the water extracts. 
Figure 7. SDS-PAGE of cell wall extracts from V. vulnificus. Left panel: Twelve percent 
gel fixed with Alcian blue prior to silver staining. Right panel: Fifteen percent gel stained 
directly with the silver nitrate protocol. Lanes A and E: E. coli O55 (8 μg);  
Lanes B and F: Petroleum ether–Chloroform–aqueous phenol (PCP) extract (16 μg);  
Lanes C and G: Water layer of the phenol/water extraction (16 μg) after enzyme treatment; 
Lanes D and H: Water layer of the phenol/water extraction (16 μg) before enzyme treatment. 
 
Further information on the chemical constituents of both LOS and PS from V. vulnificus, came from 
gas chromatography–mass spectrometry (GC-MS) analysis of the corresponding acetylated methyl 
glycosides. As for the LOS (Figure 8, upper panel), composition analysis detected the occurrence of  
L-glycero-D-manno-heptose, glucosamine and glucose but not Kdo (2-keto-3-deoxy-D-manno-octulosonic 
acid), the hallmark monosaccharide of LOS. Therefore, suspecting the presence of phosphate on this 
residue, LOS was treated with aqueous hydrogen fluoride (HF) and the analysis repeated (Figure 8, 
lower panel). The chromatogram contained two additional peaks, of which the one at 28.2 min was the 
A B C D E F G H 
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main peak of Kdo, while the one at 26.2 min was another type of heptose together with the minor peak 
produced from Kdo during this chemical procedure. Lipid composition was inferred by GC-MS 
analysis as well and showed the presence of C12:0 3-OH, C14:0, C14:0 2-OH and C14:0 3-OH  
(data not shown). 
Figure 8. Gas chromatography-mass spectrometry (GC-MS) chromatograms of the acetylated 
methyl glycosides of the lipooligosaccharide (LOS) fraction from V. vulnificus. The upper 
profiles indicate the monosaccharide composition of the LOS without hydrogen fluoride 
(HF) treatment and does not contain 2-keto-3-deoxy-D-manno-octulosonic acid (Kdo); the 
low profile is obtained after HF treatment of the sample. Peaks barred are impurities. 
 
As for the PS composition (Figure 9), residues characteristic of the LOS were below the detection 
limit, even when HF treatment was performed (data not shown). This polysaccharide contained mainly 
a 6-deoxy-hexosamine residue and an amino uronic acid residue. The ring stereochemistry of both 
these monosaccharides could not be determined at this stage because of the lack of appropriate 
standards and will be the object of further work. 
Figure 9. GC-MS chromatograms of the acetylated methyl glycosides of V. vulnificus 
polysaccharide (PS). Ribose peak is a reminiscence of the RNA contaminating the sample. 
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3. Discussion 
The role of microglia activation in central nervous system infections [25] as well as the involvement 
of O2
−
 generation in the mechanism of neuroinflammation and neurodegeneration has received 
considerable attention over the past two decades [26,30,67]. One significant activator of microglia is 
LPS [68], which may activate microglia via the lipid A portion of the macromolecule, and then 
stimulate release of O2
−
 as well as additional proinflammatory mediators such as matrix 
metalloproteinases, arachidonic acid metabolites, cytokines and chemokines [26].  
The first aim of our investigation was to test the hypothesis that LPS purified from human clinical 
V. vulnificus strain MO6-24/O might activate rat brain microglia and result in O2
−
 release in vitro. Our 
experimental data lends support to our working hypothesis and the following deductions: First, as 
previously reported [27,38], a 17 h incubation of microglia with E. coli LPS resulted in an initial  
dose-dependent enhancement of PMA-stimulated O2
−
 release followed by a progressive inhibition at 
greater than 1 ng/mL, which paralleled an increase in LDH release. Second, V. vulnificus MO6-24/O 
LPS-treated microglia generated O2
−
 as depicted by a bell-shaped dose-response curve that in contrast 
to E. coli LPS peaked at 10 ng/mL, whereupon a progressive attenuation of O2
−
 generation 
concomitant to increased LDH release was observed. Third, the observed right shift of the bell-shaped 
dose-response curve depicting O2
−
 generation by microglia treated with V. vulnificus MO6-24/O LPS 
indicates that this particular V. vulnificus LPS was less potent than E. coli LPS. Future studies should 
be undertaken to determine whether peak O2
−
 generation by V. vulnificus MO6-24/O LPS require  
18-24 h to develop, as observed with E. coli LPS-treated microglia [27]. 
Our second aim was to investigate whether concomitant with O2
−
 generation, V. vulnificus MO6-24/O 
LPS-treated microglia might release pro-inflammatory mediators, as we have observed with both  
E. coli LPS [27] and, more recently, with M. aeruginosa LPS-treated microglia [38]. Our data supports 
the following observations: First, confirming the above mentioned studies, after a 17 h in vitro incubation 
with E. coli LPS, microglia released both TXB2 and MMP-9, as well as the following cytokines and 
chemokines in the following rank order: MIP-2/CXCL2 > MIP-1α/CCL3 > CINC-2α&β/CXCL3 >  
IL-6 > TNF-α > IL-1α > MCP-1/CCL2. Second, and for the first time to our knowledge, concomitant 
with significant O2
−
 release, V. vulnificus MO6-24/O LPS-treated microglia generated not only TXB2 
and MMP-9, but also proinflammatory cytokines and chemokines in the following rank order:  
MIP-2/CXCL2 > CINC-2α & β/CXCL3 > IL-6 > MIP-1α/CCL3 > TNF-α > IL-1α > MCP-1/CCL2. 
Third, similar to O2
−
 generation, and supporting the notion that V. vulnificus MO6-24/O LPS was less 
potent but more effective than E. coli LPS, with the exception of MIP-1α, all the pro-inflammatory 
mediators investigated were released in larger quantities in vitro. Fourth, the progressive in vitro 
attenuation of PMA-elicited O2
−
 generation in V. vulnificus MO6-24/O LPS-treated microglia correlated 
with both the concentration-dependent LDH release as well as the presence of TXB2, MMP-9, and the 
cytokines and chemokines that were investigated. Our current study suggests, but does not conclusively 
prove, that the studied proinflammatory mediators may contribute to the mechanism of V. vulnificus 
MO6-24/O LPS-induced cytotoxicity to microglia in vitro. This intriguing possibility remains to be 
investigated in future studies. 
It is important to reflect on several potential new lines of inquiry that have emerged from the 
observed effects of V. vulnificus MO6-24/O LPS on rat neonatal microglia in vitro. First, because the 
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present study was completed with V. vulnificus MO6-24/O LPS, an archetypical clinical V. vulnificus 
strain [7,8], it would be important to determine whether LPS isolated from other V. vulnificus strains, 
particularly those from the environment, would also be bioactive in the in vitro rat microglia model. 
Second, because our experimental paradigm used neonatal brain microglia, an important next study 
would be to determine whether V. vulnificus MO6-24/O LPS might activate adult rat microglia, which 
release higher levels of PGE2 than neonatal microglia [69], and may perhaps differ in their capacity to 
generate O2
−
, as well as other inflammatory mediators. Third, determining whether treatment of human 
microglia with V. vulnificus LPS in vitro would also show an in vitro biphasic O2
−
 generation should 
be investigated, because E. coli LPS would prime human microglia O2
−
 release in vitro [70]. Fourth,  
in vivo studies should be undertaken to determine whether systemic inflammation caused by  
V. vulnificus MO6-24/O LPS may be pathogenic to the brain immune system, perhaps being less 
potent but more efficacious than E. coli LPS, as we have observed in our in vitro studies, because this 
V. vulnificus biotype has been shown to be lethal to mice [14] and induce cytokine release from human 
peripheral blood leukocytes [19]. The induction of reactive oxygen species by V. vulnificus LPS is also 
intriguing in light of recent work suggesting that the inflammatory response is attenuated in peripheral 
blood mononuclear cells from chronic alcohol users with evidence of oxidative stress following  
in vitro exposure to live V. vulnificus bacterial cells [71]. Fifth, further studies on the chemical 
structure of V. vulnificus LPS are necessary to determine its potential relationship with the observed 
bioactivity in this study. We are hopeful that further investigation of the immunotoxicology of  
V. vulnificus LPS on brain microglia both in vitro and in vivo will contribute to the development of 
novel therapeutic strategies to protect and treat humans exposed to both clinical and environmental 
sources of V. vulnificus strains.  
4. Experimental Section 
4.1. Reagents 
Escherichia coli LPS (E. coli) (O26:B6) was from Difco Laboratories, Detroit, MI, USA, and  
V. vulnificus LPS (1.075 × 10
5
 endotoxin units/mg), prepared from V. vulnificus strain MO6-24/O LPS 
as described [19], was used in experiments depicted in Figures 1–6 and Table 1. Dulbecco’s modified 
Eagle medium (DMEM) with high glucose (4500 mg/L), Hanks’ balanced salt solution (HBSS), 
penicillin (P), streptomycin (S) and trypsin (0.25%)-EDTA (1 mM) were from GIBCO Laboratories, 
Life Technologies Inc., Grand Island, NY, USA; heat-inactivated fetal bovine serum certified (FBS) 
was from Hyclone, Logan, UT, USA; ferricytochrome c type III (from horse heart) (FCC), superoxide 
dismutase (from bovine liver) (SOD), phorbol 12-myristate 13-acetate (PMA) were from Sigma 
Chemical Co., St. Louis, MO, USA. PMA was maintained at −20 C as a 8 mM stock solution  
in DMSO. 
4.2. LPS Contamination 
All glassware and metal spatulas were baked for 4 h at 210 C to inactivate LPS [72]. Sterile and 
LPS-free 225 cm
2
 vented cell culture flasks were from BD Biosciences, San Jose, CA, USA; 24-well  
flat-bottom culture clusters were from Costar
®
, Corning Inc., Corning, NY, USA; disposable 
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serological pipettes were from Greiner Bio-One, Monroe, NC, USA. Sterile and pyrogen-free 
Eppendorf Biopur pipette tips were from Brinkmann Instruments, Inc., Westbury, NY, USA.  
4.3. Isolation of Rat Neonatal Microglia 
Experiments were performed in adherence to National Institutes of Health guidelines on the use of 
experimental animals, with protocols approved by Midwestern University's Research and Animal Care 
Committee. Rat brain neonatal microglia were isolated and characterized as previously described [27]. 
Briefly, cerebral cortices of 1–2 day-old Sprague-Dawley rats from Charles Rivers Laboratories, 
Portage, MI, USA, were surgically removed, placed in cold DMEM containing 120 U/mL P and  
12 μg/mL S, the meninges removed, and brain tissue minced and dissociated with trypsin-EDTA at 
35.9 C for 3–5 min. The mixed glial cell suspension was plated in 225 cm2 vented cell culture flasks 
with DMEM medium supplemented with 10% FBS containing 120 U/mL P and 12 μg/mL S, and 
grown in a humidified 5% CO2 incubator at 35.9 C for 12–14 days. Upon confluence (Day 14) and 
every week thereafter, microglia were detached using an orbital shaker (150 rpm, 0.5 h, 35.9 C,  
5% CO2), centrifuged (400× g, 25 min, 4 C), and cell number and viability assessed by trypan blue 
exclusion. In our laboratory, rat neonatal microglia yields averaged 1.1 × 10
6
 microglia per tissue 
culture flask (225 cm
2
) per week. Depending on the particular experimental design (see below), 
microglia averaging > than 95% viability were plated in 24-well cell culture clusters, with DMEM 
supplemented with 10% FBS containing 120 U/mL P and 12 μg/mL S, and placed in a humidified  
5% CO2 incubator at 35.9 C 24 h prior to the experiments. 
4.4. Activation of Microglia with LPS (Experimental Design) 
To determine the in vitro effect of V. vulnificus MO6-24/O LPS on rat neonatal microglia activation 
and inflammatory mediator release (O2
−
, eicosanoids, matrix metalloproteinases, cytokines, and 
chemokines), 2 × 10
5
 rat neonatal microglia were seeded in DMEM + 10% FBS + 120 U/mL P +  
12 μg/mL S into each well of nonpyrogenic polystyrene 24-well flat-bottom culture clusters (Costar®, 
Corning Inc., Corning, NY, USA), and stimulated with 0.1–105 ng/mL V. vulnificus LPS for 17 h in a 
humidified 5% CO2 incubator at 35.9 C. E. coli LPS (0.1–100 ng/mL) was used as a control in all the 
experiments described herein [27]. After the 17h incubation, conditioned media (1 mL) from each 
tissue culture well was aspirated and split into two aliquots. One aliquot (0.1 mL) was used to measure 
lactic dehydrogenase (LDH) levels, as a measure of cell viability [39]. The remaining aliquot (0.9 mL) 
was frozen (−84 C) until determination of eicosanoids, cytokines, chemokines, and matrix 
metalloproteinases, as described below. Once the conditioned media had been removed, both  
V. vulnificus and E. coli LPS–treated microglia cells were washed with warm (37 °C) HBSS, and O2
−
 
was determined as described below. 
4.5. Assay for Superoxide Anion (O2
−
) Generation 
O2
−
 generation was determined by the superoxide dismutase (SOD)-inhibitable reduction of 
ferricytochrome C (FCC) [27]. Briefly, PMA (1 μM)-triggered O2
−
 release from either E. coli or  
V. vulnificus LPS-activated microglia was measured in the presence of FCC (50 μM) and HBSS, with 
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or without SOD (700 Units), which inhibited >95% of FCC reduction, during a 70 min incubation in a 
humidified 5% CO2 incubator at 35.9 C. All experimental treatments were run in duplicate and in a 
final volume of 1 mL. Changes in FCC absorbance were measured at 550 nm using a Beckman  
DU-800 spectrophotometer. Differences in the amount of reduced FCC in the presence and absence of 
SOD were used to determine microglia O2
−
 generation by employing the molecular extinction 
coefficient of 21.0 × 10
3
 M
−1
 cm
−1
 and expressed in nmol.  
4.6. Assay for Lactic Dehydrogenase (LDH) 
To assess cell viability of microglia treated with either V. vulnificus LPS or E. coli LPS as described 
in our experimental design, conditioned media was harvested following preincubation and LDH 
release was determined as described [27,39]. Microglia LDH release was expressed as a percent of 
total LDH released by 0.1% Triton X-100-lysed microglia. Because the fetal bovine serum contained 
LDH (data not shown), unless LDH release from LPS-treated microglia was greater than 15% of that 
observed from Triton X-100 (0.1%)-treated microglia (total LDH), LPS treatment was considered to 
have had no effect on microglia viability.  
4.7. Assay for Thromboxane B2 (TXB2) Generation  
Following incubation of microglia with either V. vulnificus LPS or E. coli LPS for 17 h, TXB2 
generation in cell-free conditioned media was measured using a TXB2 immunoassay (Cayman 
Chemical, Ann Arbor, MI, USA), as indicated in the manufacturer’s protocol. Results were expressed 
as picogram per mL (pg/mL). The minimum detectable concentration was 7.8 pg/mL TXB2. 
4.8. Gelatinase Zymography for MMP-2 and MMP-9 Analysis  
Gelatin-containing zymograms were used to detect MMP-2 (68 kDa) and MMP-9 (92 kDa) and 
their identification was based on molecular weight. Following incubation of cultured rat neonatal 
microglia with either V. vulnificus LPS or E. coli LPS, MMP-2 and -9 release were determined in the 
cell-free conditioned media. As the rat neonatal microglia cultures were normalized for cell number, 
equal volumes of harvested media obtained from each condition were analyzed. Briefly, 90 μg of each 
protein sample were electrophoresed using a 10% polyacrylamide gel containing 0.1% gelatin. The 
gels were then incubated twice for 30 min in 1× Novex Zymogram Renaturing Buffer (Invitrogen, 
Carlsbad, CA, USA), incubated overnight in a 5% CO2 incubator at 37 C, and stained in 0.4% 
(wt/vol) Coomassie Brilliant Blue R-250 Solution (Bio-Rad, Hercules, CA, USA). Sequential 
destaining first in 40% methanol, 10% acetic acid, and then in 10% methanol, 10% acetic acid allowed 
MMP activity to be visualized as clear bands against a blue background. Images of zymograms were 
obtained using a Kodak Gel Logic 1500 Imaging System and Molecular Imaging Software (Kodak, 
Rochester, NY, USA). Semiquantitation of zymograms was performed using the UN-SCAN-IT™ gel 
automated digitizing system from Silk Scientific (Orem, UT, USA). Microglia MMP release was 
normalized between experiments by dividing values in pixels for treated samples by their  
respective controls. 
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4.9. Assays for Cytokines: TNF-α, IL-1α, IL-6 and TGF-β1 
The presence of immunoreactive cytokines TNF-α, IL-1α, IL-6, TGF-β1 in the cell-free conditioned 
media was determined using rat-specific ELISAs from Biosource International (Camarillo, CA, USA). 
The results were expressed in pg/mL. The minimum detectable cytokine concentrations were: TNF-α, 
less than 4 pg/mL; IL-1α, less than 3 pg/mL; IL-6, less than 7 pg/mL and TGF-β1, less than 15.6 pg/mL.  
4.10. Assays for Chemokines: MIP-1α/CCL3, MIP-2/CXCL2, MCP-1/CCL2 and CINC-2α/β/CXCL3 
The presence of immunoreactive chemokines in cell-free conditioned media was determined using 
rat-specific ELISAs: For MIP-1α/CCL3 from Koma Biotech, Seoul, South Korea; for MIP-2/CXCL2 
and MCP-1/CCL2 from Biosource International, Camarillo, CA, USA, and for CINC-2α/β/CXCL3 
from R & D Systems, Minneapolis, MN, USA. The results were expressed in pg/mL. The minimum 
detectable chemokine concentrations were: MIP-1α/CCL3, less than 16 pg/mL; MIP-2/CXCL2, less 
than 1 pg/mL; MCP-1/CCL2, less than 8 pg/mL; and CINC-2α/β/CXCL3, less than 0.8 pg/mL. 
4.11. Assay for the Neurotrophin Brain Derived Neurotrophic Factor (BDNF) 
BDNF generation in cell-free conditioned media was measured using a rat-specific ELISA for 
BDNF from EMD Millipore, Billerica, MA. The results were expressed in pg/mL. The minimum 
detectable concentration was less than 7.8 pg/mL.  
4.12. V. vulnificus LPS Chemical Analyses 
V. vulnificus strain MO6-24/O LPS was streaked from frozen stocks onto LB agar medium and 
incubated at 37 C overnight. Bacteria from single colonies were inoculated into 10 mL LB broth and 
shaken overnight at 37 C. Two mL of the overnight culture were spread onto each of five  
21.5 × 27 cm pans containing approximately 250 mL of LB agar medium and incubated overnight at 
37 C. Cells were harvested from the trays, suspended in 15 mL deionized water, and heat shocked at 
70 C for 7 min. The cell suspension was then frozen and lyophilized. V. vulnificus LPS was prepared 
for chemical analysis from the V. vulnificus strain MO6-24/O LPS as described [73]. LPS 
monosaccharides and lipids were analysed as acetylated O-methyl glycosides and methylesters, 
respectively, as described [66]. Dephosphorylation was carried out keeping LPS (0.5 mg) in aqueous 
HF (50%, 50 μL) at room temperature overnight. The solution was evaporated under a stream of air 
and the dried material was analysed after transformation into the corresponding acetylated methyl 
glycosides. GC-MS analyses were performed with an Agilent 6850 coupled to MS Agilent 5973, 
equipped with a SPB-5 capillary column (Supelco, 30 m × 0.25 mm i.d., flow rate, 0.8 mL min
−1
) and 
He as carrier gas. Electron impact mass spectra were recorded with an ionization energy of 70 eV and 
an ionizing current of 0.2 mA. The temperature program used for the analyses was the following: 
150 °C for 5 min, 150→300 °C at 3 °C/min, 300 °C for 5 min. 
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4.13. Statistical Analysis 
Data was expressed as mean ± SEM from two to four independent experiments (n), each experiment 
with triplicate determinations. Data were analyzed with Prism
®
 software package Version 6 from 
GraphPad, San Diego, CA, USA. LPS-treated microglia were compared with the vehicle-treated 
microglia (control), shown as zero in the corresponding figures. One-way ANOVA followed by 
Dunnett’s post hoc procedure was performed on all sets of data. Statistical significance between the 
effect of a single dose of E. coli and V. vulnificus LPS on the generation of each mediator investigated 
(e.g., O2
−
) was determined using two-way ANOVA. Differences were considered statistically 
significant at p < 0.05 and reported in each figure legend.  
5. Conclusions 
Concentration-dependent treatment of neonatal brain microglia with V. vulnificus MO6-24/O LPS 
resulted in a significant rise in O2
−
 production, followed by progressive decrease in O2
−
 release, 
concomitant with release of LDH, and generation of TXB2, MMP-9, cytokines and chemokines. We 
hypothesize that the inflammatory mediators investigated may be involved in the mechanism of injury 
to microglia in vitro, by an as yet undetermined autocrine mechanism. Although in vitro V. vulnificus 
LPS was less potent than E. coli LPS, inflammatory mediator release was clearly more efficacious.  
A possible explanation for this result is that the in vitro microglia system is able to perceive chemical 
differences between V. vulnificus and E. coli LPS. Our chemical data show that Kdo in V. vulnificus 
LPS is fully phosphorylated and that the fatty acid pattern is similar with the exception of C14:0 2-OH 
which is absent in E. coli. These differences may be of importance in the modulation of the biological 
activity by LPS and more insights will probably be gained after the complete structure of V. vulnificus 
LPS is elucidated. 
Finally, we hypothesize that should V. vulnificus LPS gain entry into the CNS, it is possible that 
microglia may become activated, resulting in high levels of O2
−
 release as well as neuroinflammatory 
TXB2, MMP-9, cytokines and chemokines. In vivo studies with V. vulnificus LPS will be required to 
test this intriguing hypothesis.  
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